Oral contraception use in BRCA gene mutation carriers: information for counselling in routine clinical practice

The objective of this narrative review is to put risks and benefits for the use of oral contraception (OC) into perspective in counselling high-risk carriers of BRCA1 or BRCA2 gene mutations. We searched PubMed, Embase, and the Cochrane Library for studies that evaluated associations between OC use and breast or ovarian cancer among women who are carriers of BRCA1/2 mutations. All studies concordantly demonstrated an inverse correlation between OC and ovarian cancer risk in BRCA mutated women. Regarding breast cancer risk, results are conflicting with some studies reporting a slightly increased risk associated with OC use, whereas others reveal no evidence of a significant association in carriers. Numerous potential cancer risk modifiers and the modern evolution of OC can partly explain these results. OC use may also reduce the risk of extra-ovarian cancers such as those of the colon and endometrium, as observed in the general population. BRCA1/2 carriers should always receive a sensible and patient-centered contraceptive counselling because current evidence does not support recommendation against OC use, taking into account the individual profile.

BRCA1; BRCA2; Oral contraceptive; Ovarian cancer; Breast cancer; Counselling

[1] Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K, Mooij TM, Roos-Blom M, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. Journal of the American Medical Association. 2017; 317: 2402–2416.

[2] Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016; 387: 945–956.

[3] Chirlaque MD, Uhry Z, Salmerón D, Sánchez-Zapata MI, Zannoni GF, Navarro C, et al. Trends in net survival from ovarian cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention. 2017; S107–S113.

[4] Malvezzi M, Carioli G, Rodriguez T, Negri E, La Vecchia C. Global trends and predictions in ovarian cancer mortality. Annals of Oncology. 2016; 27: 2017–2025.

[5] Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1.2020. 2019.

[6] Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. 2016; 27: v103–v110.

[7] Walker JL, Powell CB, Chen L, Carter J, Bae Jump VL, Parker LP, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015; 121: 2108–2120.

[8] Kingsberg SA, Larkin LC, Liu JH. Clinical effects of early or surgical menopause. Obstetrics & Gynecology. 2020; 135: 853–868.

[9] Rocca WA, Gazzuola-Rocca L, Smith CY, Grossardt BR, Faubion SS, Shuster LT, et al. Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study. Mayo Clinic Proceedings. 2016; 91: 1577–1589.

[10] Rocca WA. Difficult decisions in women at high genetic risk for cancer: toward an individualized approach. Menopause. 2020; 27: 727–729.

[11] Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371: 303–314.

[12] Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European Journal of Cancer. 2010; 46: 2275–2284.

[13] Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. Journal of Clinical Oncology. 2013; 31: 4188–4198.

[14] Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Archives of Gynecology and Obstetrics. 2020; 301: 875–884.

[15] Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiology, Biomarkers & Prevention. 2005; 14: 350–356.

[16] Del Pup L, Codacci-Pisanelli G, Peccatori F. Breast cancer risk of hormonal contraception: counselling considering new evidence. Critical Reviews in Oncology/Hematology. 2019; 137: 123–130.

[17] Narod SA, Risch H, Moslehi R, Dørum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. The New England Journal of Medicine. 1998; 339: 424–428.

[18] Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine. 2001; 345: 235–240.

[19] McGuire V. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. American Journal of Epidemiology. 2004; 160: 613–618.

[20] Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British Journal of Cancer. 2004; 91: 1911–1915.

[21] Gronwald J, Byrski T, Huzarski T, Cybulski C, Sun P, Tulman A, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Research and Treatment. 2006; 95: 105–109.

[22] McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet. Oncology. 2007; 8: 26–34.

[23] Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the international BRCA1/2 carrier cohort study. Cancer Epidemiology Biomarkers & Prevention. 2009; 18: 601–610.

[24] Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer. Human Reproduction Update. 2010; 16: 631–650.

[25] Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Review of Anticancer Therapy. 2011; 11: 1197–1207.

[26] Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. Journal of the National Cancer Institute. 2014; 106: dju091.

[27] Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Research and Treatment. 2014; 143: 579–586.

[28] Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, et al. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertility and Sterility. 2015; 103: 1305–1312.

[29] Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A, et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Research. 1997; 57: 3678–3681.

[30] Narod SA, Dubé M, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 2002; 94: 1773–1779.

[31] Heimdal K, Skovlund E, Møller P. Oral contraceptives and risk of familial breast cancer. Cancer Detection and Prevention. 2002; 26: 23–27.

[32] Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiology, Biomarkers & Prevention. 2006; 15: 1863–1870.

[33] Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group. Journal of Clinical Oncology. 2007; 25: 3831–3836.

[34] Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiology, Biomarkers & Prevention. 2008; 17: 3170–3178.

[35] Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. Journal of Clinical Oncology. 2008; 26: 4282–4288.

[36] Pasanisi P, Hédelin G, Berrino J, Chang-Claude J, Hermann S, Steel M, et al. Oral contraceptive use and BRCA penetrance: a case-only study. Cancer Epidemiology Biomarkers & Prevention. 2009; 18: 2107–2113.

[37] Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Research and Treatment. 2010; 120: 175–183.

[38] Rieder V, Salama M, Glöckner L, Muhr D, Berger A, Tea M, et al. Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. Molecular Genetics & Genomic Medicine. 2015; 10: 172–177.

[39] Park B, Hopper JL, Win AK, Dowty JG, Sung HK, Ahn C, et al. Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers. Oncotarget. 2017; 8: 102110–102118.

[40] Schrijver LH, Olsson H, Phillips KA, Terry MB, Goldgar DE, Kast K, et al. Oral contraceptive use and breast cancer risk: retrospective and prospective analyses from a BRCA1 and BRCA2 mutation carrier cohort study. JNCI Cancer Spectrum. 2018; 2: pky023.

[41] Dehlendorf C, Krajewski C, Borrero S. Contraceptive counseling: best practices to ensure quality communication and enable effective contraceptive use. Clinical Obstetrics and Gynecology. 2014; 57: 659–673.

[42] Hunter DJ. Oral contraceptives and the small increased risk of breast cancer. The New England Journal of Medicine. 2017; 377: 2276–2277.

[43] Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR. Gynaecological challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingooophorectomy and hormone replacement therapy. Gynecological Endocrinology. 2010; 26: 568–577.

[44] Jernström H, Loman N, Johannsson OT, Borg A, Olsson H. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases have undergone BRCA mutation testing. European Journal of Cancer. 2005; 41: 2312–2320.

[45] Kumle M, Weiderpass E, Braaten T, Persson I, Adami H, Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian- Swedish women’s lifestyle and health cohort study. Cancer Epidemiology, Biomarkers & Prevention. 2002; 11: 1375–1381.

[46] Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Breast cancer among very young premenopausal women (United States). Cancer Causes &Control. 2003; 14: 151– 160.

[47] Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine. 2017; 377: 2228–2239.

[48] Toss A, Grandi G, Cagnacci A, Marcheselli L, Pavesi S, De Matteis E, et al. The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation. Oncotarget. 2017; 8: 9144–9154.

[49] Grandi G, Toss A, Cagnacci A, Marcheselli L, Pavesi S, Facchinetti F, et al. Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history. Clinical Breast Cancer. 2018; 18: e15–e24.

[50] Grandi G, Sammarini M, Chiara Del Savio M, Toss A, Facchinetti F. Combined hormonal contraceptives in BRCA gene mutation carriers: why not? The European Journal of Contraception & Reproductive Health Care. 2019; 24: 417–419.

[51] Maguire K, Westhoff C. The state of hormonal contraception to- day: established and emerging noncontraceptive health benefits. American Journal of Obstetrics and Gynecology. 2011; 205: S4– S8.

[52] Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute. 2002; 94: 1358– 1365.

[53] Segev Y, Iqbal J, Lubinski J, Gronwald J, Lynch HT, Moller P, et al. Hereditary Breast Cancer Study Group. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations. Gynecologic Oncology. 2013; 130: 127–131.

[54] Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk-reducing salpingooophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncology. 2016; 2: 1434–1440.

[55] Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, et al. BRCA1 and BRCA2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. Journal of the National Cancer Institute. 2018; 110: 1178–1189.

[56] Davidson BA, Moorman PG. Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer. Expert Opinion on Drug Safety. 2014; 13: 1375– 1382.

[57] Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives. 2017; 216: 580.e1–580.e9.

[58] Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation. Breast Cancer Research and Treatment. 2011; 129: 557–563.